Edition:
United Kingdom

Mylan NV (MYL.O)

MYL.O on Nasdaq

35.53USD
20 Jul 2018
Change (% chg)

$-0.11 (-0.31%)
Prev Close
$35.64
Open
$35.61
Day's High
$36.02
Day's Low
$35.40
Volume
3,172,150
Avg. Vol
4,205,539
52-wk High
$47.82
52-wk Low
$29.39

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $20,534.19
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  MYL.O Industry Sector
P/E (TTM): 31.22 30.93 32.76
EPS (TTM): 1.23 -- --
ROI: 2.39 15.07 14.61
ROE: 5.71 16.60 16.34

U.S. court rejects Allergan bid to shield patents through tribe deal

A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan PLC to shield patents from review by an administrative court by transferring them to a Native American tribe.

20 Jul 2018

UPDATE 2-U.S. court rejects Allergan bid to shield patents through tribe deal

July 20 A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan PLC to shield patents from review by an administrative court by transferring them to a Native American tribe.

20 Jul 2018

Mylan signs U.S. license deal on Humira with AbbVie

AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.

17 Jul 2018

Mylan signs U.S. license deal on Humira with AbbVie

July 17 AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.

17 Jul 2018

Indivior warning on anti-opioid drug competition sends shares tumbling

British drugmaker Indivior warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.

17 Jul 2018

BRIEF-Mylan Adds To Central Nervous System Portfolio With Launch Of Generic Exelon® Patch

* MYLAN ADDS TO CENTRAL NERVOUS SYSTEM PORTFOLIO WITH LAUNCH OF GENERIC EXELON® PATCH

09 Jul 2018

EXCLUSIVE-BMS hires banks for 1 billion euro-plus sale of French OTC drug unit - sources

LONDON, July 5 U.S. pharmaceuticals giant Bristol-Myers Squibb has hired two banks to find a buyer for its French over-the-counter (OTC) drugs business, which could be valued at more than 1 billion euros in a potential deal, sources familiar with the matter told Reuters.

05 Jul 2018

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

29 Jun 2018

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

29 Jun 2018

FDA finds deficiencies in Mylan's generic Advair; shares fall

Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment.

13 Jun 2018

Earnings vs. Estimates